Why and where an HIV cure is needed and how it might be achieved

Despite considerable global investment, only 60% of people who live with HIV currently receive antiretroviral therapy. The sustainability of current programmes remains unknown and key incidence rates are declining only modestly. Given the complexities and expenses associated with lifelong medication...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature (London) 2019-12, Vol.576 (7787), p.397-405
Hauptverfasser:	Ndung’u, Thumbi, McCune, Joseph M., Deeks, Steven G.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/1426 692/308/153 692/53/2422 692/699/255/1901 Analysis Anti-HIV Agents - administration & dosage Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral therapy Biological effects Care and treatment Cell adhesion & migration Combined Modality Therapy Demographic aspects Distribution Drug resistance Drug therapy Funding Genomes Global Health Health care disparities Health Resources Health Services Needs and Demand Highly active antiretroviral therapy HIV HIV infection HIV Infections - drug therapy HIV Infections - epidemiology HIV Infections - immunology HIV Infections - therapy HIV-1 - drug effects HIV-1 - genetics HIV-1 - immunology Human immunodeficiency virus Humanities and Social Sciences Humans Infections Intervention Medically underserved areas multidisciplinary Needs Assessment Receptors, CCR5 - deficiency Receptors, CCR5 - genetics Regulatory approval Review review-article Science Science (multidisciplinary) T-Lymphocytes, Cytotoxic - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!